Clinical Significance of O-6-Methylguanine-DNA-Methyltransferase Promoter Methylation in Patients with Esophageal Carcinoma: A Systematic Meta-Analysis

Zhang, Yan; Tong, Ti

doi:10.1159/000481342

Cited by 5 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, MGMT methylation frequency in neoplastic tissue was higher than in the normal mucosa [87,141]. MGMT methylation was more frequent in poorly or moderately differentiated oesophageal tumours associated with depth of invasion, nodal status, the existence of metastasis and clinical stage [85,87,142]. Among cancer patients who received chemotherapy with alkylating agents, those displaying MGMT methylation had better prognosis than those without MGMT methylation [87].…”

Section: Dna Methyltransferasesmentioning

confidence: 98%

Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes

Lopes

Correia

Henrique

et al. 2020

IJMS

View full text Add to dashboard Cite

Oesophageal cancer is a life-threatening disease, accounting for high mortality rates. The poor prognosis of this malignancy is mostly due to late diagnosis and lack of effective therapies for advanced disease. Epigenetic alterations may constitute novel and attractive therapeutic targets, owing to their ubiquity in cancer and their reversible nature. Herein, we offer an overview of the most important studies which compared differences in expression of enzymes that mediate epigenetic alterations between oesophageal cancer and normal mucosa, as well as in vitro data addressing the role of these genes/proteins in oesophageal cancer. Furthermore, The Cancer Genome Atlas database was interrogated for the correlation between expression of these epigenetic markers and standard clinicopathological features. We concluded that most epigenetic players studied thus far are overexpressed in tumours compared to normal tissue. Furthermore, functional assays suggest an oncogenic role for most of those enzymes, supporting their potential as therapeutic targets in oesophageal cancer.

show abstract

Section: Dna Methyltransferasesmentioning

confidence: 98%

Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes

Lopes

Correia

Henrique

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…O 6 -methylguanine-DNA methyltransferase (MGMT) is a widely studied specific DNA damage reversal repair protein that protects chromosomes from mutation, carcinogenesis, and cytotoxic effects of alkylating agents [7]. In previous studies, MGMT status was shown to be related to the occurrence and invasion of non-small cell lung cancer (NSCLC) [8], melanoma [9], malignant glioma [10], esophageal cancer [11], and prostate cancer [12]. MGMT also affected the chemotherapeutic effect of different tumor patients, but the results are controversial [8,9,13].…”

Section: Introductionmentioning

confidence: 99%

Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis

Tan

2020

Bioscience Reports

View full text Add to dashboard Cite

Background: O6-methylguanine-DNA methyltransferase (MGMT) is a specific DNA damage reversal repair protein. The influence of MGMT status on alkylating agent sensitivity in patients with neuroendocrine neoplasms (NENs) is controversial. We conducted a meta-analysis to assess the influence of MGMT status on the therapeutic sensitivity of alkylating agents in patients with NENs. Methods: We searched PubMed, EmBase, and Cochrane library public databases through 3 July 2019. The objective response rate (ORR) was the outcome data of interest. Subgroup analysis was performed according based on MGMT methylation and expression of MGMT protein. Results: Eleven studies were included in the meta-analysis. The proportion of patients with NENs that achieved an ORR after alkylating agent treatment was higher in the MGMT-deficient group than the non-deficient group (OR: 5.00; 95% CI: 3.04–8.22; P < 0.001; I2: 3%). Similar results were noted in the MGMT methylation and MGMT protein expression subgroups. Conclusion: Patients with NENs and MGMT methylation or low protein expression had a higher ORR proportion than patients without MGMT methylation or high protein expression. The MGMT status can be used as a biological indicator of the response to alkylating agent treatment in patients with NENs.

show abstract

“…Thus, the promoter methylation of MGMT was widely regarded as a promising biomarker for the detection of early carcinoma. Previous researches concentrated upon this in other cancers like esophageal cancer[8, 9], lung cancer[10–12], glioma[13, 14], colon cancer[15–18], gastric cancer[19], neck squamous cell carcinoma[20, 21], ovarian cancer[22] and breast cancer[23]. In 2001, Virmani et al .…”

Section: Introductionmentioning

confidence: 99%

Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis

2019

View full text Add to dashboard Cite

BackgroundIn this research, an meta-analysis was performed for assessment of the associations between O6-methyguanine-DNA methyltransferase (MGMT) promoter hypermethylation possessing low-grade intraepithelial lesion (LSIL), high-grade intraepithelial lesion (HSIL), cervical cancer (CC), and clinicopathological characters of CC.MethodsLiterature selection were conducted through searching PubMed, Web of science, EMBASE, China National Knowledge Infrastructure and Wanfang databases (up to November 2018). An assessment of associations between MGMT methylation and LSIL, HSIL, CC risk and clinicopathological characteristics was performed through pooled odds ratios (ORs) with relevant 95% confidence intervals (CIs). Subgroup analyses, meta-regressions and Galbraith plots were conducted to conduct an exploration on the possible sources of heterogeneity. The genome-wide DNA methylation array studies were extracted from Gene Expression Omnibus (GEO) databases for validation of these outcomes.ResultsIn this meta-analysis of 25 published articles, MGMT hypermethylation gradually elevated the rates among control group (12.16%), LSIL (20.92%), HSIL (36.33%) and CC (41.50%) specimens. MGMT promoter methylation was significant associated with the increased risk of LSIL by 1.74-fold (P<0.001), HSIL by 3.71-fold (P<0.001) and CC by 7.08-fold (P<0.001) compared with control. A significant association between MGMT promoter methylation with FIGO stage was also found (OR = 2.81, 95% CI: 1.79–4.41, p<0.001). The results of GEO datasets showed that 5 CpG sites in MGMT with a great diagnostic value for the screening of cervical cancer.ConclusionThe meta-analysis indicated the association between MGMT promoter hypermethylation and squamous intraepithelial lesion and cervical cancer. MGMT methylation detection might have a potential value to be an epigenetic marker for the clinical diagnosis of cervical cancer.

show abstract

Clinical Significance of O-6-Methylguanine-DNA-Methyltransferase Promoter Methylation in Patients with Esophageal Carcinoma: A Systematic Meta-Analysis

Cited by 5 publications

References 41 publications

Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes

Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes

Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis

Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis

Contact Info

Product

Resources

About